Identifying patients for aggressive cholesterol lowering: the risk curve concept
- PMID: 17134640
- DOI: 10.1016/j.amjcard.2006.06.039
Identifying patients for aggressive cholesterol lowering: the risk curve concept
Abstract
The National Cholesterol Education Program's 2004 report identified more aggressive optional low-density lipoprotein (LDL) cholesterol treatment goals of <70 mg/dl for secondary prevention patients and <100 mg/dl for moderately high risk, primary prevention patients. Although LDL cholesterol reduction is the first step in reducing cardiovascular risk, it may be difficult for clinicians to visualize the risk reduction benefit for patients from various risk interventions. The concept of a "risk curve," or the absolute risk of a patient for subsequent cardiovascular events over a range of LDL cholesterol values, is proposed. In conclusion, placing a patient on the appropriate risk curve may facilitate an individualized clinical management strategy that takes into account the patient's absolute benefit from further LDL cholesterol reduction as well as from shifting the risk curve downward through non-LDL cholesterol interventions.
Similar articles
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. doi: 10.1016/j.jacc.2004.07.001. J Am Coll Cardiol. 2004. PMID: 15358046 Review.
-
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. doi: 10.1161/01.ATV.0000133317.49796.0E. Arterioscler Thromb Vasc Biol. 2004. PMID: 15297292 Review.
-
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.Am J Geriatr Pharmacother. 2007 Sep;5(3):185-94. doi: 10.1016/j.amjopharm.2007.10.002. Am J Geriatr Pharmacother. 2007. PMID: 17996658
-
[Statins--attaining goal values--with reference to recent studies].Wien Med Wochenschr. 1999;149(5-6):144-5. Wien Med Wochenschr. 1999. PMID: 10408006 German.
-
Rationale for aggressive lipid lowering in high-risk patients.J Am Osteopath Assoc. 2011 Apr;111(4 Suppl 3):eS7-12. J Am Osteopath Assoc. 2011. PMID: 21593473 Review.
Cited by
-
Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.Vasc Health Risk Manag. 2009;5(1):31-43. doi: 10.2147/vhrm.s3190. Epub 2009 Apr 8. Vasc Health Risk Manag. 2009. PMID: 19436666 Free PMC article. Review.
-
Benefits associated with achieving optimal risk factor levels for the primary prevention of cardiovascular disease in older men.J Clin Lipidol. 2012 Jan-Feb;6(1):58-65. doi: 10.1016/j.jacl.2011.10.019. Epub 2011 Nov 7. J Clin Lipidol. 2012. PMID: 22264575 Free PMC article. Clinical Trial.
-
Low-Density Lipoprotein Cholesterol, Type 2 Diabetes and Progression of Aortic Stenosis: The RED-CARPET Heart Valve Subgroup Cohort Study.Rev Cardiovasc Med. 2024 Aug 7;25(8):276. doi: 10.31083/j.rcm2508276. eCollection 2024 Aug. Rev Cardiovasc Med. 2024. PMID: 39228497 Free PMC article.
-
Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol.PLoS One. 2016 Nov 8;11(11):e0166246. doi: 10.1371/journal.pone.0166246. eCollection 2016. PLoS One. 2016. PMID: 27824924 Free PMC article.
-
Is a statin as part of a polypill the answer?Curr Atheroscler Rep. 2009 Jan;11(1):15-22. doi: 10.1007/s11883-009-0003-0. Curr Atheroscler Rep. 2009. PMID: 19080723 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical